Extraordinary meeting of the Committee for Medicinal Products for Human Use (CHMP): 1 September 2022
This extraordinary meeting is organised to discuss the evaluation of two applications for adapted mRNA COVID-19 vaccines which more closely match the original strain and the BA.1 Omicron subvariant. One application was submitted by Moderna for Spikevax (previously COVID-19 Vaccine Moderna) and one by Pfizer/BioNTech for Comirnaty.
The aim of the meeting is to conclude the evaluation of the two applications, if possible.
The Committee for Medicinal Products for Human Use (CHMP) is responsible for preparing the European Medicines Agency's opinions on all questions concerning human medicines.